SCHEMBL4776893

SCHEMBL4776893

NC(C=O)C(c1ccc(Br)s1)N1CCN(C(=O)c2cc(Cl)ccc2C(F)(F)F)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 4/20 0.39
MGLL Q99685 2/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 2/20 0.33
CYP2C9 P11712 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CHRM1 P11229 1/20 0.33
RECQL P46063 1/20 0.33
PROKR1 Q8TCW9 1/20 0.33
GPR183 P32249 1/20 0.33
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ENPP2 Q13822 1/20 0.32
ABL1 P00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4837579 0.90 SCD (0.38) SCDMGLLPOLBHPGDHSD17B10
SCHEMBL4780056 0.85 SCD (0.38) SCDMGLLHPGDLMNATP53
SCHEMBL4778523 0.82 SCD (0.40) SCDMGLLLMNATP53ALOX15
SCHEMBL4775840 0.75 HDAC8 (0.45) SCDMGLLTSHRHDAC1HDAC6
SCHEMBL4775889 0.73 SCN5A (0.42) SCDMGLL
SCHEMBL4778154 0.73 ABL1 (0.34) LMNAHSD17B10RECQLKMT2AKDM4E
SCHEMBL4772658 0.71 CACNA2D1 (0.39) SCDCYP2C9
SCHEMBL4774662 0.69 CACNA1B (0.41) SCDPOLBHPGDLMNATSHR
SCHEMBL4753765 0.68 HCRTR1 (0.44) SCDMGLLCYP2C9KDM4E
Hydrochloric Acid SCHEMBL3466376 0.67 HCRTR1 (0.43) SCDMGLLCYP2C9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed